NDA 208193 · Rosemont
Ozobax Ds
Baclofen · Oral · gamma-Aminobutyric Acid-ergic Agonist
OrphanLast checked: Nov 20, 2026Latest source record: Oct 12, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Sep 18, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
123
30 Phase 3, 6 recruiting
FAERS reports
85,283
56,416 serious, 6,383 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 8, 2026.
Baclofen oral solution is indicated for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Baclofen oral solution may also be of some value in patients with spinal cord injuries and other spinal cord diseases. Limitations of Use Baclofen oral solution is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. Baclofen oral solution is a gamma-aminobutyric acid (GABA-ergic) agonist indicated for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. ( 1 ) Baclofen oral solution may also be of some value in patients with spinal cord injuries and other spinal cord diseases. ( 1 ) Limitations of Use Baclofen oral solution is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. ( 1 )
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- OZOBAX DS · BACLOFEN 10MG/5ML · SOLUTION, ORAL · Prescription · TE AA
- OZOBAX · BACLOFEN 5MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Baclofen" as an intervention, any sponsor and status, largest first.
- The Analgesic Efficacy and Safety of Baclofen in Patients With Herpes ZosterPivotal-lookingRecruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07378046 · 750 participants (planned) · Start Dec 15, 2025 · Primary completion Sep 30, 2027
Drug: Baclofen combined conventional therapy; Conventional therapy · For: Herpes Zoster; Pain
Sites: Beijing, China
- An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain ServicePivotal-lookingNot yet recruiting
University of California, San FranciscoAcademic, hospital or other
NCT07296770 · 474 participants (planned) · Start Oct 1, 2026 · Primary completion Dec 1, 2028
Drug: Pharmacologic Pain Management · For: Postsurgical Pain Management; Postsurgical Pain, Chronic; Opioid Use After Surgery
Sites: San Francisco, California
- A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump InhibitorsPivotal-lookingCompleted
VA Office of Research and DevelopmentFederal agency
NCT01265550 · 366 participants · Start Aug 13, 2012 · Primary completion Dec 30, 2016
Drug: baclofen; Desipramine · For: GERD
Sites: Birmingham, Alabama; Tucson, Arizona; Loma Linda, California · 15 sites in all
- Efficacy Study of Arbaclofen to Treat Spasticity in Multiple SclerosisPivotal-lookingCompleted
RVL Pharmaceuticals, Inc.Industry
NCT01743651 · 353 participants · Start Nov 2012 · Primary completion Apr 2014
Drug: arbaclofen; baclofen and 1 more · For: Spasticity; Multiple Sclerosis
Sites: Cullman, Alabama; Long Beach, California; Aurora, Colorado · 48 sites in all
- Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A PatientsPivotal-lookingStatus unknown
Pharnext S.C.A.Academic, hospital or other
NCT04762758 · 350 participants (planned) · Start Mar 30, 2021 · Primary completion Apr 19, 2024
Drug: (RS)-baclofen, naltrexone hydrochloride and D-sorbitol; Placebo · For: Charcot-Marie-Tooth Disease
Sites: Los Angeles, California; Sacramento, California; New Britain, Connecticut · 50 sites in all
- A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MSPivotal-lookingCompleted
RVL Pharmaceuticals, Inc.Industry
NCT03319732 · 323 participants · Start Apr 3, 2018 · Primary completion Jan 27, 2020
Drug: Arbaclofen · For: Multiple Sclerosis; Spasticity, Muscle
Sites: Fresno, California
- Baclofen for the Treatment of Alcohol DrinkersPivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT01604330 · 323 participants · Start May 29, 2012 · Primary completion Sep 2014
Drug: Baclofen; Placebo · For: Alcoholism
Sites: Paris, France
- Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back PainPivotal-lookingCompleted
Montefiore Medical CenterAcademic, hospital or other
NCT03068897 · 320 participants · Start May 3, 2017 · Primary completion Jul 11, 2018
Drug: Metaxalone; Tizanidine and 2 more · For: Low Back Pain
Sites: The Bronx, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue6,301
- drug ineffective5,648
- pain5,558
- fall5,451
- nausea4,694
- headache4,446
- gait disturbance4,135
- off label use3,878
- dizziness3,633
- urinary tract infection3,526
- asthenia3,445
- multiple sclerosis relapse3,419
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 646 |
| 2005 | 757 |
| 2006 | 675 |
| 2007 | 795 |
| 2008 | 886 |
| 2009 | 1,033 |
| 2010 | 1,500 |
| 2011 | 1,738 |
| 2012 | 2,502 |
| 2013 | 3,001 |
| 2014 | 4,251 |
| 2015 | 5,157 |
| 2016 | 7,596 |
| 2017 | 7,023 |
| 2018 | 7,705 |
| 2019 | 6,672 |
| 2020 | 5,778 |
| 2021 | 5,493 |
| 2022 | 5,107 |
| 2023 | 5,680 |
| 2024 | 4,233 |
| 2025 | 4,069 |
| 2026 | 2,983 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ozobax Ds (Baclofen)
2024 spending
$32K
Beneficiaries
11
24 claims
Per beneficiary
$2,902
$3.30 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $31,920 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Dystonia.
Snaith A, Wade D · BMJ Clin Evid 2014 · Systematic Review
- Pharmacologic Interventions for Intractable and Persistent Hiccups: A Systematic Review.
Polito NB, Fellows SE · J Emerg Med 2017 · Systematic Review
- Cluster headache.
Matharu M, Silver N · BMJ Clin Evid 2008 · Systematic Review
- Multiple sclerosis.
Nicholas R, Rashid W · BMJ Clin Evid 2012 · Systematic Review
- Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis.
Bahji A, Bach P, Danilewitz M, et al. · J Addict Med 2022 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Trigeminal neuralgia.
Zakrzewska JM, Linskey ME · BMJ Clin Evid 2009 · Systematic Review
Sponsor: Rosemont · Also marketed as Ozobax
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.